• LAST PRICE
    11.0400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    10.0000/ 1
  • Ask / Lots
    11.4000/ 1
  • Open / Previous Close
    11.3200 / 11.0400
  • Day Range
    Low 10.9000
    High 11.3600
  • 52 Week Range
    Low 3.4200
    High 30.4000
  • Volume
    19,201
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 11.04
TimeVolumeGYRE
09:32 ET60911.32
09:36 ET64811.36
09:45 ET10011.225
09:56 ET10011.235
10:06 ET20011.12
10:08 ET66511.1216
10:15 ET11611.14
10:21 ET10011.13
10:24 ET20011.175
10:44 ET50011.045
10:53 ET10010.94
10:55 ET10011.15
10:57 ET30011.07
11:06 ET10011.12
11:11 ET10011.1
11:15 ET10011.03
11:26 ET10011.08
11:31 ET28111.09
11:44 ET10011.03
11:58 ET60011.055
12:05 ET50011.095
12:16 ET10011.04
12:34 ET20010.97
12:48 ET12910.9
12:50 ET10010.98
01:10 ET30011.05
01:24 ET20011.01
01:39 ET10011.01
01:42 ET10011.09
02:42 ET10011.23
02:44 ET10011.24
03:14 ET80011.22
03:20 ET10011.18
03:32 ET10010.98
03:43 ET10011.15
03:59 ET10011.04
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGYRE
Gyre Therapeutics Inc
944.0M
-5.9x
---
United StatesWVE
WAVE Life Sciences Ltd
762.9M
-12.1x
---
United StatesNRIX
Nurix Therapeutics Inc
900.2M
-5.7x
---
United StatesPRTA
Prothena Corporation PLC
1.1B
-6.3x
---
United StatesCVAC
CureVac NV
823.2M
-2.8x
---
United StatesSAGE
SAGE Therapeutics Inc
722.2M
-1.4x
---
As of 2024-06-15

Company Information

Gyre Therapeutics, Inc. is a biotechnology company. The Company is engaged in the research, development, manufacturing and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). The Company is also advancing a diverse pipeline in China through a controlling interest in Beijing Continent, including pirfenidone, F573, F528, and F230. Pirfenidone is used for idiopathic pulmonary fibrosis and is undergoing Phase III trials in dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, along with a Phase I trial in diabetic kidney disease. F573 is being investigated for acute-on-chronic liver failure, while F528 and F230 are being evaluated for chronic obstructive pulmonary disease and pulmonary arterial hypertension, respectively.

Contact Information

Headquarters
12770 High Bluff Drive, Suite 150SAN DIEGO, CA, United States 92130
Phone
619-949-3681
Fax
302-636-5454

Executives

Non-Executive Chairman of the Board
Ying Luo
President, Director
Songjiang Ma
Chief Executive Officer, Director
Han Ying
Interim Chief Financial Officer
Ruoyu Chen
Chief Operating Officer
Weiguo Ye

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$944.0M
Revenue (TTM)
$140.6M
Shares Outstanding
85.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.06
EPS
$-1.88
Book Value
$0.64
P/E Ratio
-5.9x
Price/Sales (TTM)
6.7
Price/Cash Flow (TTM)
---
Operating Margin
-42.20%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.